Home » Posts tagged with » USA
Gilead Sciences wraps up $21bn acquisition of Immunomedics

Gilead Sciences wraps up $21bn acquisition of Immunomedics

Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has now become a fully-owned subsidiary of Gilead Sciences. The common stock of Immunomedics will be delisted from the Nasdaq Global Market. Immunomedics, which has been acquired for $88 per share […]

Gilead Sciences bags Remdesivir FDA approval for Covid-19 treatment

Remdesivir FDA approval : Gilead Sciences, a California-based biopharma company, has bagged approval from the US Food and Drug Administration (FDA) for its antiviral drug Veklury (remdesivir) for Covid-19 treatment in patients requiring hospitalization. This makes remdesivir the first approved treatment for coronavirus in the US. Remdesivir FDA approved indication : Veklury has been approved […]

Continue reading …
VelosBio begins phase 2 trial of VLS-101 in solid tumors

VelosBio, a San Diego-based biopharma company, said that it has dosed the first patient in a phase 2 clinical trial of its investigational antibody-drug conjugate (ADC) VLS-101 in patients having solid tumors. VLS-101, which is the company’s lead product candidate, targets a cell-surface protein called ROR1. Expressed during embryofetal development, ROR1 is however not seen […]

Continue reading …
Endo International to acquire BioSpecifics Technologies for $658m

Endo International has agreed to acquire BioSpecifics Technologies, a New York-based commercial-stage biopharma company, for $88.5 per share, or an estimated enterprise value of around $658 million. The Irish pharma company and BioSpecifics Technologies have been in a strategic partnership since 2004. BioSpecifics Technologies had developing a form of injectable collagenase clostridium histolyticum (CCH), which […]

Continue reading …
Bracco Diagnostics gets FDA nod for CardioGen-82 infusion system

Bracco Diagnostics, the US subsidiary of Italian diagnostic imaging company Bracco Imaging, has secured approval from the US Food and Drug Administration (FDA) for its new CardioGen-82 infusion system. According to Bracco Diagnostics, CardioGen-82 infusion system is used for improving automation, efficiency, and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). CARDIOGEN-82 […]

Continue reading …
Lilly to acquire SARM1 inhibitor developer Disarm Therapeutics

Lilly acquisition of Disarm Therapeutics : Eli Lilly and Company (Lilly) has agreed to acquire Disarm Therapeutics, a biotech company based in Cambridge, Massachusetts, which is focused on developing a new class of disease-modifying treatments for patients with axonal degeneration. As per the terms of the deal, Lilly will pay an upfront payment of $135 […]

Continue reading …
Regeneron bags Inmazeb FDA approval for treatment of Ebola

Inmazeb FDA approval : Regeneron Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for its antibody cocktail Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of Zaire ebolavirus (Ebola virus). Formerly known as REGN-EB3, Inmazeb is now the first drug regimen to get FDA approval for Ebola treatment, covering adult and […]

Continue reading …
AstraZeneca to advance AZD7442 into phase 3 Covid-19 trials

AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is a combination of a couple of monoclonal antibodies (mAbs) extracted from convalescent patients with SARS-CoV-2 infection. It will be assessed in more than 6,000 participants at sites in and outside […]

Continue reading …
R3 Vascular raises $17.8m for devices to treat peripheral artery diseases

R3 Vascular, an early-stage US medical device company, has raised $17.8 million in a Series A financing round, led by an undisclosed corporate investor and 415 CAPITAL. The funding comprised new equity investments of $15 million and the conversion of $2.8 million of convertible notes. The Series A round also saw participation from HBM-MedFocus and Wexford […]

Continue reading …
Apellis reports positive results for pegcetacoplan in phase 2 C3G trial

Apellis Pharmaceuticals has reported positive results for pegcetacoplan from the phase 2 DISCOVERY clinical trial in patients with C3 glomerulopathy (C3G), a type of kidney disease. According to the US biopharma company, the 48-week results demonstrated that patients subjected to pegcetacoplan had sustained improvements across key clinical measures. These include a greater than 65% mean […]

Continue reading …
Page 1 of 41123Next ›Last »